Gender-Specific Association of Androgenetic Alopecia With Metabolic Syndrome in a Middle-aged Korean Population

S.M. Yi; S.W. Son; K.G. Lee; S.H. Kim; S.K. Lee; E.R. Cho; I.-H. Kim; C. Shin


The British Journal of Dermatology. 2012;167(2):306-313. 

In This Article


Of 3408 initial participants (1707 men, 1701 women), 2884 (1563 men, 1321 women) participated in this study. The mean age of participants ± SD was 55·2 ± 7·5 years (55·1 ± 7·4 in men, 55·4 ± 4·8 in women, age range above 40 years).

Prevalence Rate of Metabolic Syndrome

The overall prevalence rate of MetS as determined by NCEP ATPIII criteria among the 2884 participants was 28·0% (n = 808). The prevalence rate of MetS in the male group was 26·9% (n = 421) and in the female group was 29·3% (n = 387). In the male group, no specific trend was found in the prevalence rate of MetS among the different degrees of the AGA patient group. In contrast, the prevalence rate tended to increase with AGA severity in the female group (Table 1). Age-specific prevalence showed a tendency to increase with age in both the male and female groups. The prevalence rate of MetS was highest in the 70 years or older age groups in both groups (Table 2). The results in Table 2 also indicate that subjects with developed AGA (Norwood IV or greater in men, Ludwig type I or greater in women) in both groups had a higher prevalence of MetS than those with no to mild AGA (Norwood III or less in men, normal in women).

Association Between Metabolic Syndrome and Androgenetic Alopecia

Table 3 and Table 4 demonstrate the associations between MetS and AGA with and without adjustments for age, family history of AGA, and smoking. In men, the risk of having Norwood type IV or greater was mildly increased for subjects with MetS compared with those without MetS, but this finding was not statistically significant. The prevalence had a magnitude of 1·27-fold (95% CI 0·97–1·65) in the unadjusted model and 1·24-fold (95% CI 0·89–1·73) in the adjusted model. Table 3 also shows the comparison of severe AGA (Norwood grade V or above) with moderate AGA (Norwood grade III and IV) in men. The results revealed that severe AGA conferred a 1·41-fold (95% CI 0·93–2·14) higher risk of MetS compared with moderate AGA, but this finding was also not statistically significant. When the number of fulfilled components of MetS, rather than simply the presence of MetS, was considered, no significant association was also noted with or without AGA in men. In women, the risk of having Ludwig type I or greater was statistically significantly increased for subjects with MetS compared with those without MetS. The increased prevalence had a magnitude of 2·75-fold (95% CI 2·04–3·70; P < 0·0001) in the unadjusted model and 1·68-fold (95% CI 1·14–2·48; P = 0·01) in the adjusted model. Similar results were also observed for the number of fulfilled components of MetS (OR 1·38, 95% CI 1·00–1·91; P < 0·05). When each component of MetS was considered individually, associations for all five components (waist circumference, TG, HDL-C, blood glucose, and BP) were not statistically significant ( Table 4 ).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: